OAS2 and melanoma: In detail, ISGs were up-regulated in 8 and 8 vs. 2 (DDX58); 7 and 6 vs. 3 (IFIT1); 7 and 5 vs. 1 (IFIT2); 1 and 2 vs. 0 (JAK1); 1 and 0 vs. 0 (JAK2); 7 and 3 vs. 3 (STAT1); 11 and 11 vs. 6 (IFI27); 8 and 8 vs. 4 (IFI6); 7 and 8 vs. 3 (OAS1); 10 and 11 vs. 5 (OAS2); 11 and 13 vs. 5 (OASL); 9 and 10 vs. 3 (IRF7); 8 and 7 vs. 4 (IRF9); 12 and 12 vs. 5 (IFITM1); 4 and 5 vs. 2 (IFITM3); 8 and 9 vs. 1 (MX1); 8 and 8 vs. 6 (MX2); 10 and 12 vs. 3 (ISG15); 9 and 9 vs. 5 (ISG20); 5 and 4 vs. 4 (IFI44) and 9 and 10 vs. 7 (IFI44L) melanoma cells, treated with guadecitabine or DAC vs. AZA, respectively.